Geode Capital Management LLC Grows Stake in Cue Biopharma, Inc. (NASDAQ:CUE)

Geode Capital Management LLC increased its position in Cue Biopharma, Inc. (NASDAQ:CUE) by 24.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 631,281 shares of the company’s stock after acquiring an additional 122,454 shares during the quarter. Geode Capital Management LLC owned about 1.00% of Cue Biopharma worth $688,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CUE. LPL Financial LLC grew its holdings in Cue Biopharma by 139.5% during the 4th quarter. LPL Financial LLC now owns 42,929 shares of the company’s stock valued at $47,000 after buying an additional 25,004 shares in the last quarter. HighTower Advisors LLC grew its position in Cue Biopharma by 54.0% during the fourth quarter. HighTower Advisors LLC now owns 128,284 shares of the company’s stock valued at $140,000 after acquiring an additional 45,000 shares during the last quarter. Finally, Sigma Planning Corp lifted its stake in Cue Biopharma by 11.4% in the fourth quarter. Sigma Planning Corp now owns 447,175 shares of the company’s stock worth $487,000 after purchasing an additional 45,850 shares during the last quarter. 35.04% of the stock is currently owned by hedge funds and other institutional investors.

Cue Biopharma Price Performance

CUE opened at $0.75 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.22 and a quick ratio of 2.22. Cue Biopharma, Inc. has a 1 year low of $0.45 and a 1 year high of $2.26. The stock’s 50 day simple moving average is $0.90 and its 200 day simple moving average is $1.17. The firm has a market cap of $46.48 million, a price-to-earnings ratio of -0.84 and a beta of 2.02.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. The business had revenue of $1.80 million during the quarter, compared to analysts’ expectations of $1.70 million. Cue Biopharma had a negative return on equity of 156.38% and a negative net margin of 468.02%. During the same quarter last year, the business posted ($0.28) EPS. As a group, analysts predict that Cue Biopharma, Inc. will post -0.76 earnings per share for the current year.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.